Record-Setting Quarterly Revenue
The company achieved a record $114 million in quarterly revenue, representing a 35% year-over-year growth.
Strong Performance in Surgical and Wound Franchises
Surgical business grew by 26% and wound care by 40% year-over-year, contributing significantly to the company's overall growth.
Increased Full-Year Guidance
The company raised its full-year 2025 revenue growth outlook from low teens to mid- to high teens and expects adjusted EBITDA margin to be at least in the mid-20s.
Notable Cash Generation
The company generated $29 million in free cash flow for the quarter, with a net cash position of $124 million and expectations to exceed $150 million by year-end.
Positive Interim Analysis for EPIEFFECT
Over half of the target patients are enrolled in the EPIEFFECT trial, with favorable interim results, positioning the product for future reimbursement coverage.